You are not logged in
Visit our Twitter
Visit our LinkedIn
Experts Knowledge Share: Prevention and Management of Hearth Disease in T2D Patients: Cardiologist and Diabetologist Perspective
If you wish to view the details for the meeting, then please click the button.
Back to the Meeting Details
1. Select the correct answer. In Type 2 diabetes:
Evidence from prospective trials indicates that glycaemic control reduces the risk of cardiovascular disease
Clustering of cardiovascular risk with insulin resistance is associated with a twofold increase in cardiovascular disease
Insulin resistance is commonly associated with obesity, raised triglycerides and low levels of plasminogen activator inhibitor-1
Metformin has beneficial effects on glycaemia and insulin resistance that make it first line in prevention and management of cardiovascular disease
2. Select the false answer. In Type 2 diabetes:
SGLT2i reduces blood sugar by enhancing urinary glucose excretion
DPPIV inhibitors normalise glycaemia by shortening the half-life of GLP-1 in the circulation
SGLT2i is associated with an increased risk of urinary tract infections
GLP-1RA are available as either an injection or orally for ease of administration
3. Select the false answer. In Type 2 diabetes:
The development of heart failure causes morbidity but does not alter life expectancy
A fall in the LV ejection fraction to <50% indicates the development of systolic heart failure
A raised BNP with non-specific symptoms including tiredness and mild dyspnoea may indicate the development of diastolic heart failure
4. Select the correct answer. In the management of heart failure in Type 2 diabetes:
SGLT2i clearly demonstrate clinical benefits in both systolic and diastolic heart failure
SGLT2i are only effective in the absence of glycosuria
SGLT2i should be considered in addition to beta-blockade, ACE I and diuretic therapy as each confers added benefit
Screening for heart failure is not necessary as it is an uncommon finding in T2DM
5. Select the false answer. In the management of chronic renal impairment in Type 2 diabetes:
SGLT2i cause an initial fall in eGFR followed by a plateauing effect which persists for at least 4 years
Clinical trials provide clear evidence over placebo in the management of renal impairment
SGLT2i should only be used if the eGFR has fallen to <30
6. Do you have any questions you would like to ask the faculty?
COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally.
Disclaimer: The material and content contained in the website engage.cor2ed.com is for healthcare professionals only. Although every effort is made to ensure that the material within this website is accurate and timely, it is provided for informational and educational purposes only. The information provided is not intended as a substitute for medical professional help, advice, diagnosis or treatment and may not be applicable to every case or country.
© Copyright 2021 | All Rights Reserved